Improvements in quality of life and disease-ralated symptoms in phase Ⅰ trials of the selective oral epidermal growth factor receptor tyrosinc kinase inhibitor ZD1839 in non-small-cell lung cancer and other solid tumors

查看全文 作　　者：Lorusso PM; Heebst RS; Rischin D; 出　　处：《Clin Cancer Rest》索引2003年第9卷第6期,共0页